小梁切除术与MicroShunt在美国Medicare系统中的成本效果比较
该成本-效用分析基于随机对照试验及关键临床试验数据,用Markov模型评估开角型青光眼患者接受小梁切除术或MicroShunt的社会成本效用。1年时MicroShunt组预期成本6318美元、获得0.85个QALY,小梁切除术组成本4260美元、获得0.86个QALY,增量成本效用比为187680美元/QALY,MicroShunt被小梁切除术支配。在50000美元支付意愿阈值下,MicroShunt具有成本效果的概率为6.4%。
要点
- 1年时MicroShunt组预期成本6318美元,小梁切除术组4260美元。
- MicroShunt组获得0.85个QALY,小梁切除术组获得0.86个QALY。
- 增量成本效用比为187680美元/QALY,MicroShunt被小梁切除术支配。
核心结论
- 在青光眼手术治疗中,小梁切除术似乎比MicroShunt更具支配性。
- 需要更多独立的长期研究来评估MicroShunt及其他结膜下微支架装置的临床使用。
研究设计与样本
- 采用随机对照试验及其他关键临床试验的疗效与安全性结果进行成本-效用分析。
- 使用TreeAge软件构建确定性Markov模型,时间跨度为1年,分析开角型青光眼治疗的成本与效果。
- 健康状态包括Hodapp-Parrish-Anderson青光眼分期(轻度、中度、晚期、盲)及死亡。
- 两组均接受额外降眼压药物以控制眼压,治疗效果以平均降眼压药物数量及眼压降低幅度衡量,直接影响健康状态间的转移概率。
- 进行情景分析(更长的时间跨度)、单因素敏感性分析和概率敏感性分析。
主要发现
- 1年时MicroShunt组预期成本为6318美元,小梁切除术组为4260美元。
- MicroShunt组获得0.85个QALY,小梁切除术组获得0.86个QALY。
- 增量成本效用比为187680美元/QALY,MicroShunt被小梁切除术支配。
- 在使用最佳情况输入参数(包括设备费为0美元)的单因素敏感性分析中,MicroShunt仍被支配。
- 在50000美元支付意愿阈值下,MicroShunt具有成本效果的概率为6.4%;在长达20年的时间跨度内,支配地位持续存在。
关键数值与推荐
- 增量成本效用比:187680美元/QALY。
- 支付意愿阈值50000美元下MicroShunt具有成本效果的概率为6.4%。
- MicroShunt组1年预期成本6318美元,小梁切除术组4260美元。
- MicroShunt组0.85个QALY,小梁切除术组0.86个QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多独立的长期研究来评估MicroShunt及其他结膜下微支架装置的临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the societal cost-utility of the MicroShunt compared with trabeculectomy for the surgical management of glaucoma in the US Medicare system. DESIGN: Cost-utility analysis using efficacy and safety results of a randomized controlled trial and other pivotal clinical trials. PARTICIPANTS: Markov model cohort of patients with open-angle glaucoma. METHODS: Open-angle glaucoma treatment costs and effects were analyzed with a deterministic model over a 1-year horizon using TreeAge software. Health states included the Hodapp-Parrish-Anderson glaucoma stages (mild, moderate, advanced, blind) and death. Both treatment arms received additional ocular hypotensive agents to control intraocular pressure (IOP). Treatment effect was measured as mean number of ocular hypotensive medications and reduction in IOP, which had a direct impact on transition probabilities between health states. Analyses of scenarios were performed with longer time horizons. One-way sensitivity and probabilistic sensitivity analyses were conducted to assess the impact of alternative model inputs. Both treatment arms were subject to reported complication rates, which were factored in the model. MAIN OUTCOME MEASURES: Incremental cost per quality-adjusted life-year (QALY) gained. RESULTS: At 1 year, the MicroShunt had an expected cost of US dollars (USD) 6318 compared with USD 4260 for trabeculectomy. MicroShunt patients gained 0.85 QALYs compared with 0.86 QALYs for trabeculectomy, resulting in a dominated incremental cost-utility ratio of USD 187 680. Dominance is a health economic term used to describe a treatment option that is both more costly and less effective than the alternative. The MicroShunt remained dominant in 1-way sensitivity analyses using best-case input parameters (including a device fee of USD 0). At a willingness-to-pay threshold of USD 50 000, the likelihood of the MicroShunt being cost-effective was 6.4%. Dominance continued in longer time horizons, up to 20 years. CONCLUSIONS: Trabeculectomy appears to be a dominant treatment strategy over the MicroShunt in the surgical management of glaucoma. More independent, long-term studies are required for the MicroShunt and other subconjunctival microstent devices to evaluate their use in clinical practice.
引用
- Atik A, Fahy ET, Rhodes LA, et al. Comparative Cost-effectiveness of Trabeculectomy versus MicroShunt in the US Medicare System. Ophthalmology. 2022. PMID: 35636620. doi:10.1016/j.ophtha.2022.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。